The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 5, 2000, Pages 387-393

  Shi, Bin ^a   Yaremko, Bohdan ^a   Hajian, Gerald ^a   Terracina, Gaby ^a   Bishop, W Robert ^a   Liu, Ming ^a   Nielsen, Loretta L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Docetaxel; Farnesyl protein transferase inhibitor; Paclitaxel; Ras transgenic mice

Indexed keywords

DOCETAXEL; LONAFARNIB; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

EID: 0033729718     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000170     Document Type: Article

References (43)

1. Ras genes
2. Ras oncogenes in human cancer: A review
3. Paclitaxel (Taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells
4. Cytotoxicity of the anticancer agents cisplatin and Taxol during cell proliferation and the cell cycle
5. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic
6. Farnesyltransferase inhibitors and anti-Ras therapy
7. Bcl-2 is the guardian of microtubule integrity
8. Mechanism of action of Taxol
9. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation
10. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro
11. Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS
12. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity
13. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice
14. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
15. Preclinical evaluation of docetaxel (Taxotere)
16. Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression
17. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models, and wap-ras transgenic mice
18. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice
19. Function and regulation of Ras
20. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to Taxol and epothilones
21. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
22. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956
23. Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene
24. Evaluation of the wap-ras transgenic mouse as a model system for testing anticancer drugs
25. In wap-ras transgenic mice, tumor phenotype, but not cyclophosphamide-sensitivity is affected by genetic background
26. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models
27. Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity
28. Spatial regression models, response surfaces, and process optimization
29. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells
30. A strategy for developing transgenic assays for screening anti-neoplastic drugs which affect tubulin polymerization
31. Screening of a library of phage-displayed peptides identifies human bcl-2 as a Taxol-binding protein
32. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo
33. Taxol: A novel investigational antimicrotubule agent
34. Genetic and pharmacological suppression of oncogenic mutations in RAS genes of yeast and humans
35. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel
36. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras
37. Ras CAAX peptidomimetic FTI 276 selectively blocks tumour growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion
38. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine
39. Prenylation-dependent association of Ki-ras with microtubules: Evidence for a role in subcellular trafficking
40. Mechanisms of Taxol-induced cell death are concentration dependent
41. Loss of-normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
42. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
43. Characterization of H, K- and N-Ras as in vitro substrates for isoprenyl protein transferases